TY - JOUR
T1 - Effect of vitamin D supplementation on total and allergen-specific IgE in children with asthma and low vitamin D levels
AU - Rosser, Franziska J.
AU - Han, Yueh Ying
AU - Forno, Erick
AU - Bacharier, Leonard B.
AU - Phipatanakul, Wanda
AU - Guilbert, Theresa W.
AU - Cabana, Michael D.
AU - Ross, Kristie
AU - Blatter, Joshua
AU - Durrani, Sandy
AU - Luther, James
AU - Wisniewski, Stephen R.
AU - Celedón, Juan C.
N1 - Funding Information:
This study was funded by the US National Institutes of Health (NIH; grant no. HL119952 ). The project was also supported by the Pediatric Clinical and Translational Research Center at the University of Pittsburgh Medical Center Children’s Hospital of Pittsburgh through the NIH (grant no. UL1TR001857 ). F.J.R.’s contribution was supported by the NIH (grant no. KL2 TR001856 ). Pharmavite LLC provided the vitamin D and placebo capsules for the study, and Glaxo Smith Kline provided the Flovent given to study participants.
Funding Information:
This study was funded by the US National Institutes of Health (NIH; grant no. HL119952). The project was also supported by the Pediatric Clinical and Translational Research Center at the University of Pittsburgh Medical Center Children's Hospital of Pittsburgh through the NIH (grant no. UL1TR001857). F.J.R.?s contribution was supported by the NIH (grant no. KL2 TR001856). Pharmavite LLC provided the vitamin D and placebo capsules for the study, and Glaxo Smith Kline provided the Flovent given to study participants.
Funding Information:
Disclosure of potential conflict of interest: W. Phipatanakul has served as consultant for Glaxo Smith Kline (GSK), Genentech, Novartis, Regeneron, Sanofi, and Teva; has received clinical trial support or medications from Genentech, Novartis, Regeneron, Sanofia, Circassia, Monaghen, Thermo Fisher, Alk Abello, Lincoln Diagnostics, GSK, Kaleo, and Merck; and reports funding to the institution by Genentech, Regeneron, Novartis, and the US National Institutes of Health (NIH), all for projects unrelated to the current work. T. W. Guilbert reports personal fees from the American Board of Pediatrics (Pediatric Pulmonary Subboard), GSK, and Teva; grants from Astra-Zeneca and Novartis; grants and personal fees from Sanofi/Regeneron; and other support from UpToDate, all unrelated to the current work. M. D. Cabana is a member of the United States Preventive Services Task Force (USPSTF). J. C. Celedón has received Asmanex from Merck for another NIH-funded study, unrelated to the current work. The contents of this study do not necessarily represent the views of the USPSTF. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2021 American Academy of Allergy, Asthma & Immunology
PY - 2022/1
Y1 - 2022/1
N2 - Background: Observational studies have yielded inconsistent findings for the relation between vitamin D level and total IgE or allergic sensitization. Objective: To determine whether vitamin D supplementation reduces levels of total IgE and IgE to each of 2 common indoor allergens in children with asthma and low vitamin D levels. Methods: Total IgE, IgE to Dermatophagoides pteronyssinus, and IgE to Blattella germanica were measured at the randomization and exit visits for 174 participants in the Vitamin D Kids Asthma Study, a multicenter, double-blind, randomized placebo-controlled trial of vitamin D3 supplementation (4000 IU/d) to prevent severe exacerbations in children with persistent asthma and vitamin D levels less than 30 ng/mL. Multivariable linear regression was used for the analysis of the effect of vitamin D supplementation on change in each IgE measure. Results: Participants were followed for an average of 316 days. At the exit visit, more subjects in the vitamin D arm achieved a vitamin D level equal to or more than 30 ng/mL compared with those in the placebo arm (87% vs 30%; P <.001). In a multivariable analysis, vitamin D3 supplementation had no significant effect on change in total IgE, IgE to Dermatophagoides pteronyssinus, or IgE to Blattella germanica between the exit and randomization visits (eg, for log10 total IgE, β = 0.007; 95% CI, −0.061 to 0.074; P =.85). Conclusions: Vitamin D supplementation, compared with placebo, has no significant effect on serum levels of total IgE, IgE to dust mite, or IgE to cockroach in children with asthma and low vitamin D levels.
AB - Background: Observational studies have yielded inconsistent findings for the relation between vitamin D level and total IgE or allergic sensitization. Objective: To determine whether vitamin D supplementation reduces levels of total IgE and IgE to each of 2 common indoor allergens in children with asthma and low vitamin D levels. Methods: Total IgE, IgE to Dermatophagoides pteronyssinus, and IgE to Blattella germanica were measured at the randomization and exit visits for 174 participants in the Vitamin D Kids Asthma Study, a multicenter, double-blind, randomized placebo-controlled trial of vitamin D3 supplementation (4000 IU/d) to prevent severe exacerbations in children with persistent asthma and vitamin D levels less than 30 ng/mL. Multivariable linear regression was used for the analysis of the effect of vitamin D supplementation on change in each IgE measure. Results: Participants were followed for an average of 316 days. At the exit visit, more subjects in the vitamin D arm achieved a vitamin D level equal to or more than 30 ng/mL compared with those in the placebo arm (87% vs 30%; P <.001). In a multivariable analysis, vitamin D3 supplementation had no significant effect on change in total IgE, IgE to Dermatophagoides pteronyssinus, or IgE to Blattella germanica between the exit and randomization visits (eg, for log10 total IgE, β = 0.007; 95% CI, −0.061 to 0.074; P =.85). Conclusions: Vitamin D supplementation, compared with placebo, has no significant effect on serum levels of total IgE, IgE to dust mite, or IgE to cockroach in children with asthma and low vitamin D levels.
KW - Vitamin D
KW - asthma
KW - children
KW - immunoglobulin E
UR - http://www.scopus.com/inward/record.url?scp=85108833850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108833850&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.05.037
DO - 10.1016/j.jaci.2021.05.037
M3 - Article
C2 - 34118248
AN - SCOPUS:85108833850
SN - 0091-6749
VL - 149
SP - 440-444.e2
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 1
ER -